Regeneron Pharmaceuticals, Inc. (LON:0R2M)
London · Delayed Price · Currency is GBP · Price in USD | Market Cap | 54.49B +11.8% |
| Revenue (ttm) | 11.30B +5.9% |
| Net Income | 3.35B -1.7% |
| EPS | 31.10 +4.1% |
| Shares Out | n/a |
| PE Ratio | 16.27 |
| Forward PE | 13.92 |
| Dividend | 2.68 (0.37%) |
| Ex-Dividend Date | Feb 20, 2026 |
| Volume | 1 |
| Average Volume | 453 |
| Open | 719.88 |
| Previous Close | 720.16 |
| Day's Range | 705.00 - 719.88 |
| 52-Week Range | 477.01 - 820.00 |
| Beta | 0.30 |
| RSI | 45.58 |
| Earnings Date | Apr 29, 2026 |
About Regeneron Pharmaceuticals
Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines to treat various diseases worldwide. The company develops product candidates to treat eye, allergic and inflammatory, cardiovascular, metabolic, neurological, infectious, and rare diseases; and cancer, hematologic conditions. It also offers EYLEA injections for wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; retinopathy of prematurity; Dupixent ... [Read more]
Financial Performance
In 2025, Regeneron Pharmaceuticals's revenue was $14.34 billion, an increase of 0.99% compared to the previous year's $14.20 billion. Earnings were $4.50 billion, an increase of 2.09%.
Financial numbers in USD Financial StatementsNews
Regeneron Pharmaceuticals Transcript: Bank of America Global Healthcare Conference 2026
Secured relief from government pricing mandates and committed $9B to U.S. R&D and manufacturing through 2030. Dupixent leads in multiple indications, with strong COPD uptake and next-gen candidates in development. EYLEA HD shows robust growth, and oncology pipeline advances with fianlimab and LIBTAYO.
Regeneron Named to Dow Jones Best-in-Class World Index for Global Responsibility Leadership for Seven Consecutive Years
Regeneron also earns spot on Dow Jones Best-in-Class North America Index for six consecutive years Recognition complements the company's recent announcement that it will provide its new gene therapy f...
Regeneron, Sanofi present results from Dupixent Phase 4 trial
Regeneron Pharmaceuticals (REGN) and Sanofi (SNY) presented results from the REMODEL Phase 4 trial demonstrating that Dupixent showed significant and clinically meaningful improvements in both esophag...
Dupixent® (dupilumab) Demonstrates Improved Esophageal Function in Eosinophilic Esophagitis (EoE) Phase 4 Trial
Dupixent showed significant and clinically meaningful improvements in both esophageal distensibility as well as disease-related structural changes and inflammation in the esophagus in adult patients w...
Regeneron price target raised to $995 from $975 at Guggenheim
Guggenheim analyst Yatin Suneja raised the firm’s price target on Regeneron (REGN) to $995 from $975 and keeps a Buy rating on the shares after a “strong performance” in Q1.
Regeneron price target lowered to $788 from $796 at Morgan Stanley
Morgan Stanley analyst Terence Flynn lowered the firm’s price target on Regeneron (REGN) to $788 from $796 and keeps an Equal Weight rating on the shares. Pipeline progress continues to…
Regeneron price target lowered to $796 from $801 at Truist
Truist lowered the firm’s price target on Regeneron (REGN) to $796 from $801 and keeps a Buy rating on the shares. The company’s Q1 earnings boasted top and bottom-line beats,…
Regeneron price target lowered to $762 from $779 at RBC Capital
RBC Capital lowered the firm’s price target on Regeneron (REGN) to $762 from $779 and keeps a Sector Perform rating on the shares after its Q1 results. Slightly soft Eylea…
Regeneron price target lowered to $917 from $923 at Barclays
Barclays lowered the firm’s price target on Regeneron (REGN) to $917 from $923 and keeps an Overweight rating on the shares.
Regeneron Pharmaceuticals Earnings Call Transcript: Q1 2026
Q1 2026 saw 19% revenue growth and 15% EPS growth, driven by strong Dupixent, EYLEA HD, and Libtayo sales. Key pipeline advances, new collaborations, and a $3B share repurchase authorization position the company for continued momentum.
Regeneron beats quarterly results estimates on strong Dupixent demand
Regeneron Pharmaceuticals beat Wall Street estimates for first-quarter profit and revenue on Wednesday, helped by strong demand for its eczema drug, Dupixent, and cancer drug, Libtayo, offsetting com...
Regeneron Reports First Quarter 2026 Financial and Operating Results
TARRYTOWN, N.Y., April 29, 2026 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced financial results for the first quarter of 2026 and provided a business update.
Regeneron weighs overseas price for Otarmeni, gene therapy for rare type of hearing loss
Regeneron will make its newly approved gene therapy Otarmeni for a rare, genetic form of hearing loss available for free in the U.S. The company hasn't decided how it will price the therapy overseas, ...
Regeneron CEO on deal with Trump admin to lower drug prices
Regeneron inked a deal with the Trump administration to lower drug prices and avoid planned tariffs. CEO Leonard Schleifer told CNBC's "Squawk Box" on Friday that "we have to support this industry," b...
Regeneron announces agreement with U.S. government to help lower drug costs
Regeneron (REGN) Pharmaceuticals announced an agreement with the U.S. government to help lower prices of several of its current and future medicines and offer a new medicine for free in…
Regeneron Announces Agreement with U.S. Government to Help Lower Drug Costs for American Patients and Will Provide Innovative New Gene Therapy for Free in the U.S.
Regeneron will provide Otarmeni™ (lunsotogene parvec-cwha) , its recently approved gene therapy for an ultra-rare form of genetic hearing loss, for free in the U.S.
Regeneron inks drug pricing deal with Trump, will offer new hearing-loss therapy for free
Regeneron agreed to lower U.S. drug prices for some Americans as part of a deal with President Donald Trump. The biotech company will also offer the first hearing-loss gene therapy for free to eligibl...
Regeneron to offer prescriptions at most favored nation prices, Trump says
U.S. President Donald Trump said on Thursday that Regeneron has agreed to offer prescriptions at most favored nation prices.
FDA Approves First-Ever Gene Therapy to Restore Hearing
Regeneron's drug restored hearing in 11 of 12 children in a rare, inherited condition that causes deafness.
FDA grants accelerated approval for Regeneron’s Otarmeni
Regeneron (REGN) Pharmaceuticals announced the U.S. Food and Drug Administration has granted accelerated approval for Otarmeni, the first gene therapy and second new molecular entity approved under th...
FDA approves Regeneron's gene therapy for inherited deafness
U.S. Food and Drug Administration has approved Regeneron's gene therapy for a rare genetic form of deafness, the company said on Thursday.
Otarmeni™ (lunsotogene parvec-cwha) Approved by FDA as First and Only Gene Therapy for Genetic Hearing Loss; Regeneron to Provide Otarmeni for Free in the U.S.
Approval in severe-to-profound and profound OTOF -related hearing loss is based on pivotal results of the CHORD trial demonstrating 80% of participants achieved or surpassed a hearing level meeting t...
Regeneron agrees to lower prices as gene therapy approved, Bloomberg says
Regeneron (REGN) reached a deal with the Trump administration to lower drug costs as it received approval for its gene therapy to treat a rare form of deafness, Gerry Smith…
White House to announce drug pricing deal with Regeneron, source says
The White House will announce a drug pricing deal with Regeneron Pharmaceuticals on Thursday, according to a source familiar with the matter.
Regeneron price target raised to $960 from $880 at TD Cowen
TD Cowen analyst Tyler Van Buren raised the firm’s price target on Regeneron (REGN) to $960 from $880 and keeps a Buy rating on the shares. The firm updated its…